134 related articles for article (PubMed ID: 36526722)
1. IL7 genetic variation and toxicity to immune checkpoint blockade in patients with melanoma.
Taylor CA; Watson RA; Tong O; Ye W; Nassiri I; Gilchrist JJ; de Los Aires AV; Sharma PK; Koturan S; Cooper RA; Woodcock VK; Jungkurth E; Shine B; Coupe N; Payne MJ; Church DN; Naranbhai V; Groha S; Emery P; Mankia K; Freedman ML; Choueiri TK; Middleton MR; Gusev A; Fairfax BP
Nat Med; 2022 Dec; 28(12):2592-2600. PubMed ID: 36526722
[TBL] [Abstract][Full Text] [Related]
2. Checkpoint-blocker-induced autoimmunity is associated with favourable outcome in metastatic melanoma and distinct T-cell expression profiles.
Ye W; Olsson-Brown A; Watson RA; Cheung VTF; Morgan RD; Nassiri I; Cooper R; Taylor CA; Akbani U; Brain O; Matin RN; Coupe N; Middleton MR; Coles M; Sacco JJ; Payne MJ; Fairfax BP
Br J Cancer; 2021 May; 124(10):1661-1669. PubMed ID: 33723392
[TBL] [Abstract][Full Text] [Related]
3. Germline variants associated with toxicity to immune checkpoint blockade.
Groha S; Alaiwi SA; Xu W; Naranbhai V; Nassar AH; Bakouny Z; El Zarif T; Saliby RM; Wan G; Rajeh A; Adib E; Nuzzo PV; Schmidt AL; Labaki C; Ricciuti B; Alessi JV; Braun DA; Shukla SA; Keenan TE; Van Allen E; Awad MM; Manos M; Rahma O; Zubiri L; Villani AC; Fairfax B; Hammer C; Khan Z; Reynolds K; Semenov Y; Schrag D; Kehl KL; Freedman ML; Choueiri TK; Gusev A
Nat Med; 2022 Dec; 28(12):2584-2591. PubMed ID: 36526723
[TBL] [Abstract][Full Text] [Related]
4. Association of Immune-Related Adverse Events, Hospitalization, and Therapy Resumption With Survival Among Patients With Metastatic Melanoma Receiving Single-Agent or Combination Immunotherapy.
Watson AS; Goutam S; Stukalin I; Ewanchuk BW; Sander M; Meyers DE; Pabani A; Cheung WY; Heng DYC; Cheng T; Monzon JG; Navani V
JAMA Netw Open; 2022 Dec; 5(12):e2245596. PubMed ID: 36480204
[TBL] [Abstract][Full Text] [Related]
5. Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8
Watson RA; Tong O; Cooper R; Taylor CA; Sharma PK; de Los Aires AV; Mahé EA; Ruffieux H; Nassiri I; Middleton MR; Fairfax BP
Sci Immunol; 2021 Oct; 6(64):eabj8825. PubMed ID: 34597125
[TBL] [Abstract][Full Text] [Related]
6. T cell characteristics associated with toxicity to immune checkpoint blockade in patients with melanoma.
Lozano AX; Chaudhuri AA; Nene A; Bacchiocchi A; Earland N; Vesely MD; Usmani A; Turner BE; Steen CB; Luca BA; Badri T; Gulati GS; Vahid MR; Khameneh F; Harris PK; Chen DY; Dhodapkar K; Sznol M; Halaban R; Newman AM
Nat Med; 2022 Feb; 28(2):353-362. PubMed ID: 35027754
[TBL] [Abstract][Full Text] [Related]
7. IL7 Genetic Variation Predicts Immune-Related Adverse Events.
Cancer Discov; 2023 Mar; 13(3):OF2. PubMed ID: 36607229
[TBL] [Abstract][Full Text] [Related]
8. Analysis of Human Leukocyte Antigen DR Alleles, Immune-Related Adverse Events, and Survival Associated With Immune Checkpoint Inhibitor Use Among Patients With Advanced Malignant Melanoma.
Akturk HK; Couts KL; Baschal EE; Karakus KE; Van Gulick RJ; Turner JA; Pyle L; Robinson WA; Michels AW
JAMA Netw Open; 2022 Dec; 5(12):e2246400. PubMed ID: 36512357
[TBL] [Abstract][Full Text] [Related]
9. Melanoma patients with immune-related adverse events after immune checkpoint inhibitors are characterized by a distinct immunological phenotype of circulating T cells and M-MDSCs.
Lepper A; Bitsch R; Özbay Kurt FG; Arkhypov I; Lasser S; Utikal J; Umansky V
Oncoimmunology; 2023; 12(1):2247303. PubMed ID: 37593676
[TBL] [Abstract][Full Text] [Related]
10. Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor.
Bai X; Wang X; Ma G; Song J; Liu X; Wu X; Zhao Y; Liu X; Liu Z; Zhang W; Zhao X; Zheng Z; Jing J; Shi H
Front Immunol; 2021; 12():793831. PubMed ID: 34987517
[TBL] [Abstract][Full Text] [Related]
11. Immune checkpoint blockade toxicity among patients with cancer presenting to the emergency department.
Peyrony O; Tieghem Y; Franchitti J; Ellouze S; Morra I; Madelaine-Chambrin I; Flicoteaux R; Baroudjian B; Azoulay E; Chevret S; Fontaine JP
Emerg Med J; 2019 May; 36(5):306-309. PubMed ID: 30910911
[TBL] [Abstract][Full Text] [Related]
12. Bacteroides vulgatus and Bacteroides dorei predict immune-related adverse events in immune checkpoint blockade treatment of metastatic melanoma.
Usyk M; Pandey A; Hayes RB; Moran U; Pavlick A; Osman I; Weber JS; Ahn J
Genome Med; 2021 Oct; 13(1):160. PubMed ID: 34641962
[TBL] [Abstract][Full Text] [Related]
13. Lower frequencies of circulating suppressive regulatory T cells and higher frequencies of CD4
Kovacsovics-Bankowski M; Sweere JM; Healy CP; Sigal N; Cheng LC; Chronister WD; Evans SA; Marsiglio J; Gibson B; Swami U; Erickson-Wayman A; McPherson JP; Derose YS; Eliason AL; Medina CO; Srinivasan R; Spitzer MH; Nguyen N; Hyngstrom J; Hu-Lieskovan S
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38233101
[TBL] [Abstract][Full Text] [Related]
14. Aging-associated and CD4 T-cell-dependent ectopic CXCL13 activation predisposes to anti-PD-1 therapy-induced adverse events.
Tsukamoto H; Komohara Y; Tomita Y; Miura Y; Motoshima T; Imamura K; Kimura T; Ikeda T; Fujiwara Y; Yano H; Kamba T; Sakagami T; Oshiumi H
Proc Natl Acad Sci U S A; 2022 Jul; 119(29):e2205378119. PubMed ID: 35858347
[TBL] [Abstract][Full Text] [Related]
15. Incidence and Outcome of Neurologic Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors in Patients With Melanoma.
Pepys J; Stoff R; Ramon-Gonen R; Ben-Betzalel G; Grynberg S; Frommer RS; Schachter J; Asher N; Taliansky A; Nikitin V; Dori A; Shelly S
Neurology; 2023 Dec; 101(24):e2472-e2482. PubMed ID: 37652699
[TBL] [Abstract][Full Text] [Related]
16. Repurposing Azacitidine and Carboplatin to Prime Immune Checkpoint Blockade-resistant Melanoma for Anti-PD-L1 Rechallenge.
van der Westhuizen A; Lyle M; Graves MC; Zhu X; Wong JWH; Cornall K; Ren S; Pugliese L; Levy R; Majid A; Vilain RE; Bowden NA
Cancer Res Commun; 2022 Aug; 2(8):814-826. PubMed ID: 36923309
[TBL] [Abstract][Full Text] [Related]
17. HLA class II immunogenic mutation burden predicts response to immune checkpoint blockade.
Shao XM; Huang J; Niknafs N; Balan A; Cherry C; White J; Velculescu VE; Anagnostou V; Karchin R
Ann Oncol; 2022 Jul; 33(7):728-738. PubMed ID: 35339648
[TBL] [Abstract][Full Text] [Related]
18. Distinct Immune Signatures Indicative of Treatment Response and Immune-Related Adverse Events in Melanoma Patients under Immune Checkpoint Inhibitor Therapy.
Reschke R; Gussek P; Boldt A; Sack U; Köhl U; Lordick F; Gora T; Kreuz M; Reiche K; Simon JC; Ziemer M; Kunz M
Int J Mol Sci; 2021 Jul; 22(15):. PubMed ID: 34360781
[TBL] [Abstract][Full Text] [Related]
19. Peripheral CD8
Fairfax BP; Taylor CA; Watson RA; Nassiri I; Danielli S; Fang H; Mahé EA; Cooper R; Woodcock V; Traill Z; Al-Mossawi MH; Knight JC; Klenerman P; Payne M; Middleton MR
Nat Med; 2020 Feb; 26(2):193-199. PubMed ID: 32042196
[TBL] [Abstract][Full Text] [Related]
20. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]